Supplementary material

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: A 6-Month Interim Analysis

Author(s):   Rieke Alten[1], Gerd R. Burmester[2], Marco Matucci-Cerinic[3,4], Jean H. Salmon[5], Pedro Lopez-Romero[6]*, Walid Fakhouri[6], Inmaculada de la Torre[6], Liliana Zaremba-Pechmann[7], Thorsten Holzkämper[6], Bruno Fautrel[8]

Author affiliation(s): [1]Department of Internal Medicine and Rheumatology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany; [2]Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Milan, Italy; [4]Department of Experimental and Clinical Medicine, Division of Rheumatology AOUC, University of Florence, Florence, Italy; [5]University of Reims Champagne-Ardenne, Faculty of Medicine, UR 3797, Reims, F-51095, France, and Rheumatology Department, Maison Blanche Hospital, Reims University Hospitals, Reims, F-51092, France; [6]Eli Lilly and Company, Indianapolis, Indiana, USA; [7]HaaPACS, Schriesheim, Germany; [8]Sorbonne University – Assistance Publique Hôpitaux de Paris, Pitie Salpetriere Hospital, Department of Rheumatology, Paris, France and PEPITES team, Pierre Louis Institute of Epidemiology and Public Health, INSERM UMRS 11376, Paris, France

* Former Lilly employee.

Corresponding author
Rieke Alten
Address: Department of Internal Medicine and Rheumatology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany
Phone: +49 30 3264-1325
Fax: +49 30 3264-1324
Email: Rieke.Alten@schlosspark-klinik.de

Supplementary Table 1. Analysis of RA treatment discontinuations over 6 months for cohort A by treatment history (b/tsDMARD naïve or experienced), monotherapy or in combination with csDMARDs

	Cohort A Baricitinib (2 or 4 mg) (N=509)							
	Baricitinib (4 mg) (N=450)	Baricitinib (2 mg) (N=59)	Naïve to ts/bDMARDs (N=245)	One ts/bDMARD (N=67)	Two ts/bDMARDs (N=110)	More than two ts/bDMARDs (N=87)	Monotherapy (N=259)	With csDMARD (N=250)
Patients who completed the 6-month visit	291 (64.7)	45 (76.3)	156 (63.7)	45 (67.2)	79 (71.8)	56 (64.4)	171 (66.0)	165 (66.0)
Cumulative incidence of RA treatment discontinuation over 6 months, % (95% CI)[a]	17.2 (13.3–22.2)	11.7 (5.0–26.1)	10.0 (6.1–16.2)	24.8 (14.6–40.4)	16.5 (9.9–26.7)	28.0 (17.8–42.3)	13.2 (8.9–19.4)	20.0 (14.6–27.1)

Data are presented as n (%) unless otherwise indicated.

Supplementary Table 2. RA-related health care resource utilization over 6 months of treatment with baricitinib (cohort A) or any other tsDMARD or any bDMARD (cohort B) per patient and per country

	France		Germany		Italy		Spain		UK	
	Cohort A N=79	Cohort B N=74	Cohort A N=159	Cohort B N=135	Cohort A N=45	Cohort B N=73	Cohort A N=28	Cohort B N=37	Cohort A N=25	Cohort B N=52
Physician visits and hospitalizations, mean (SD)										
Visits to primary care physicians, outpatient physicians, and emergency departments	1.1 (1.5)	1.4 (2.0)	1.4 (2.3)	1.5 (2.3)	1.6 (2.7)	0.9 (1.3)	2.3 (3.7)	1.3 (2.0)	1.4 (1.6)	2.2 (2.6)
Visits to other health care professionals	0.3 (1.5)	4.1 (9.5)	1.3 (5.2)	2.6 (8.9)	0.1 (0.5)	0.1 (0.4)	1.8 (5.9)	0.5 (2.2)	0.5 (1.0)	1.1 (2.2)
Visits to other health care professionals that included an injection	0.2 (1.4)	0.6 (2.2)	0.0 (0.3)	0.2 (0.9)	0.0 (0.0)	0.0 (0.0)	0.8 (3.7)	0.2 (1.0)	0.2 (0.5)	0.1 (0.2)
Hospitalizations	0.1 (0.4)	0.0 (0.2)	0.0 (0.1)	0.0 (0.2)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.1 (0.3)
Duration of hospitalization, days	0.3 (1.6)	0.0 (0.2)	0.1 (0.5)	0.2 (1.3)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.1 (0.9)
Diagnostic imaging tests, mean (SD)										
All tests	0.3 (0.7)	0.5 (0.8)	0.7 (1.4)	0.6 (1.3)	0.3 (0.7)	0.2 (0.5)	0.5 (1.0)	0.4 (0.7)	0.3 (0.7)	0.2 (0.5)
X-ray	0.1 (0.3)	0.3 (0.6)	0.1 (0.2)	0.1 (0.3)	0.1 (0.3)	0.1 (0.3)	0.1 (0.5)	0.2 (0.5)	0.2 (0.4)	0.2 (0.5)
Ultrasound	0.1 (0.5)	0.2 (0.4)	0.5 (1.2)	0.4 (1.1)	0.1 (0.4)	0.0 (0.2)	0.3 (0.7)	0.2 (0.5)	0.1 (0.5)	0.1 (0.3)
Magnetic resonance imaging	0.0 (0.2)	0.0 (0.2)	0.0 (0.2)	0.0 (0.2)	0.0 (0.3)	0.0 (0.2)	0.1 (0.3)	0.0 (0.2)	0.1 (0.4)	0.0 (0.0)
Laboratory tests, mean (SD)										
All laboratory tests	14.2 (19.4)	12.5 (9.3)	11.5 (12.7)	14.7 (22.6)	7.1 (3.4)	8.3 (3.8)	8.5 (4.3)	7.9 (6.7)	8.0 (7.0)	9.4 (7.1)
Erythrocyte sedimentation rate tests	4.4 (9.8)	2.8 (2.2)	2.3 (2.0)	2.8 (3.4)	1.5 (0.9)	1.8 (1.0)	1.8 (1.1)	1.8 (1.3)	2.4 (2.8)	2.2 (2.6)

C-reactive protein tests	3.4 (3.0)	3.2 (2.2)	2.7 (2.7)	3.4 (3.5)	1.6 (0.9)	1.9 (1.0)	1.9 (1.0)	1.8 (1.3)	2.6 (2.7)	2.9 (2.4)
Rheumatoid factor tests	0.0 (0.2)	0.1 (0.5)	2.8 (9.2)	5.0 (20.9)	0.0 (0.2)	0.0 (0.2)	0.6 (0.9)	0.4 (0.6)	0.0 (0.0)	0.0 (0.0)
Anticyclic citrullinated peptide tests	0.1 (0.2)	0.1 (0.5)	0.4 (1.3)	0.3 (0.9)	0.0 (0.2)	0.0 (0.2)	0.3 (0.6)	0.2 (0.4)	0.0 (0.2)	0.1 (0.5)
Creatinine tests	2.9 (2.7)	3.0 (2.3)	2.2 (1.8)	2.1 (2.1)	1.6 (1.1)	1.9 (1.2)	1.9 (1.0)	1.9 (1.4)	2.8 (2.6)	3.4 (2.6)
Creatinine phosphokinase tests	0.2 (0.7)	0.3 (0.8)	0.2 (0.6)	0.1 (0.3)	0.2 (0.4)	0.2 (0.4)	0.6 (0.8)	0.4 (1.4)	0.0 (0.0)	0.0 (0.0)
Liver tests	3.2 (2.8)	3.2 (3.1)	2.1 (1.8)	2.1 (1.8)	1.7 (1.0)	2.1 (1.1)	1.8 (1.0)	1.8 (1.4)	2.8 (2.6)	3.2 (2.6)
Complete blood count tests	4.4 (9.8)	3.1 (2.3)	1.7 (2.0)	1.6 (1.7)	1.7 (1.0)	2.1 (1.1)	1.9 (0.9)	1.7 (1.4)	2.9 (2.8)	3.6 (2.5)

bDMARD, biologic disease-modifying antirheumatic drug; RA, rheumatoid arthritis; SD, standard deviation; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.

Supplementary Figure. Study design

bDMARD, biologic disease-modifying antirheumatic drug; RA, rheumatoid arthritis; T, time point; tsDMARD, targeted synthetic disease-modifying antirheumatic drug